Skip to main content

NICE TAs

29/07/2020
TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
29/07/2020
TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
29/07/2020
TA340: Ustekinumab for treating active psoriatic arthritis (replaced TA313)
28/07/2020
TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
28/07/2020
TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (replaced TA376)
28/07/2020
TA315: Canagliflozin in combination therapy for treating type 2 diabetes
28/07/2020
TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
28/07/2020
TA330: Sofosbuvir for treating chronic hepatitis C
28/07/2020
TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (replaced TA371)
28/07/2020
TA352: Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy
28/07/2020
TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
28/07/2020
TA336: Empagliflozin in combination therapy for treating type 2 diabetes
24/07/2020
TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
24/07/2020
TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
24/07/2020
TA254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
24/07/2020
TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
24/07/2020
TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
24/07/2020
TA346: Aflibercept for treating diabetic macular oedema
23/07/2020
TA345: Naloxegol for treating opioid‑induced constipation
23/07/2020
TA433: Apremilast for treating active psoriatic arthritis (replaced TA372)
Follow AWTTC: